SCHEMBL524084

SCHEMBL524084

O=C1O[C@H](COCc2ccccc2)C[C@H]1OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.58
PTPN1 P18031 2/20 0.42
CDC25B P30305 1/20 0.42
BCHE P06276 2/20 0.42
ACHE P22303 2/20 0.42
AKT1 P31749 1/20 0.42
TSHR P16473 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
CTSV O60911 1/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
CTSC P53634 1/20 0.39
CTSF Q9UBX1 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
HRH4 Q9H3N8 4/20 0.38
HRH3 Q9Y5N1 4/20 0.38
PDE4D Q08499 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28102964 1.00 LMNA (0.58) LMNAPTPN1CDC25BBCHEACHE
SCHEMBL28455222 0.87 LMNA (0.53) LMNAPTPN1CDC25BBCHEACHE
SCHEMBL435272 0.84 LMNA (0.56) LMNAPTPN1CDC25BAKT1TSHR
SCHEMBL10120775 0.84 LMNA (0.43) LMNAPTPN1CDC25BCTSVCTSL
SCHEMBL19231385 0.84 LMNA (0.43) LMNACTSVCTSLCTSBCTSS
SCHEMBL21697602 0.82 LMNA (0.51) LMNAPTPN1CDC25BBCHEACHE
SCHEMBL7154872 0.82 LMNA (0.48) LMNABCHEACHEAKT1TSHR
SCHEMBL21218201 0.82 LMNA (0.51) LMNAPTPN1CDC25BBCHEACHE
SCHEMBL16010060 0.82 LMNA (0.51) LMNAPTPN1CDC25BBCHEACHE
SCHEMBL22579610 0.81 LMNA (0.56) LMNAPTPN1CDC25BBCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509466-B2 Methods and compounds for treating paramyxoviridae virus infections GILEAD SCIENCES, INC. (US) 2025-12-30 US disclosed
EP-4591935-A2 METHODS FOR THE PREPARATION OF RIBOSIDES Gilead Sciences, Inc. (US) 2025-07-30 EP disclosed
CN-113549120-B Method for preparing ribonucleoside 吉利德科学公司 2025-04-29 CN disclosed
CN-108348526-B Methods of treating arenaviridae and coronaviridae viral infections 吉利德科学公司 2025-04-25 CN disclosed
CN-118812607-A Method for preparing ribonucleoside 吉利德科学公司 2024-10-22 CN disclosed
CN-116617233-A Methods of treating arenaviridae and coronaviridae viral infections 吉利德科学公司 2023-08-22 CN disclosed
US-20230125751-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2023-04-27 US disclosed
CN-115887465-A Methods of treating arenaviridae and coronaviridae virus infections 吉利德科学公司 2023-04-04 CN disclosed
CN-115844896-A Methods of treating arenaviridae and coronaviridae virus infections 吉利德科学公司 2023-03-28 CN disclosed
US-20230027727-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2023-01-26 US disclosed
EP-2480559-B1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-CYANO-CARBANUCLEOSIDE ANALOGS GILEAD SCIENCES INC (US) 2013-07-03 EP disclosed
US-20120027752-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. (US) 2012-02-02 US disclosed
US-20110230654-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS GILEAD SCIENCES, INC. (US) 2011-09-22 US disclosed
US-20110230654-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS GILEAD SCIENCES, INC. (US) 2011-09-22 US disclosed
US-8012942-B2 Carba-nucleoside analogs for antiviral treatment GILEAD SCIENCES, INC. (US) 2011-09-06 US disclosed
US-8012942-B2 Carba-nucleoside analogs for antiviral treatment GILEAD SCIENCES, INC. (US) 2011-09-06 US disclosed
WO-2011035250-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS GILEAD SCIENCES, INC. (US) 2011-03-24 WO disclosed
WO-2010093608-A1 CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2010-08-19 WO disclosed
US-20100203015-A1 CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2010-08-12 US disclosed
US-20100203015-A1 CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2010-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100203015-A1 CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT PNP, TYMP, MTAP LMNA 1447/4885PTPN1 2744/4885CDC25B 1817/4885
US-20120027752-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS PNP, RPIA, HPRT1 LMNA 1211/4885PTPN1 1838/4885CDC25B 3868/4885
US-20230125751-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS PNP, RPIA, HPRT1 LMNA 1211/4885PTPN1 1838/4885CDC25B 3868/4885
US-12509466-B2 Methods and compounds for treating paramyxoviridae virus infections MTAP, PNP, NSUN2 LMNA 1169/4885PTPN1 1347/4885CDC25B 3932/4885
US-20110230654-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS PNP, TYMP, CDA LMNA 1150/4885PTPN1 3598/4885CDC25B 791/4885
US-20230027727-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS PNP, ACE, ACE2 LMNA 1620/4885PTPN1 2199/4885CDC25B 3946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.